Concepedia

Author

Miloslav Beran

The University of Texas MD Anderson Cancer Center

Also Known As

Beran, M, M A Beran, M Beran, M. BERAN, M. Beran, Michal Beran, Miloslav A. Beran, Miloslav Beran

94

Publications

3.1K

Citations

27

H-Index

53

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterAnderson HospitalKarolinska InstitutetKarolinska University Hospital
MB

About

Miloslav Beran is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, hematology, and cell biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

23

817

2

Cell Biology

10

11

482

3

Health Sciences

9

9

420

4

Natural Sciences

2

2

48

5

Biochemistry

1

1

10

Miloslav Beran

×

46

Publications

2.9K

Citations

26

H-Index

YearCitations

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

Bruce D. Cheson, John M. Bennett, Hagop M. Kantarjian,

PubMed

2000

665

Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.

Bruno Calabretta, Robert B. Sims, M Valtieri,

Proceedings of the National Academy of Sciences

1991

206

Inhibition of <i>in vitro</i> granulopoiesis by autologous allogeneic human NK cells.

Mona Hansson, Miloslav Beran, Birger Andersson,

The Journal of Immunology

1982

195

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

Susan O’Brien, Hagop M. Kantarjian, M Keating,

Blood

1995

181

<i>RAS</i> Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant

Clara Ricci, Elisa Fermo, Stefania Corti,

Clinical Cancer Research

2010

136

Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia

Miloslav Beran, Hagop M. Kantarjian, S O'Brien,

Blood

1996

126

PEG‐IFN‐α‐2b therapy in BCR‐ABL–negative myeloproliferative disorders

Elias Jabbour, Hagop M. Kantarjian, Jörge E. Cortes,

Cancer

2007

113

Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction

Gloria Mattiuzzi, Elihu H. Estey, Issam Raad,

Cancer

2003

89

The association of specific “favorable” cytogenetic abnormalities with secondary leukemia

Hagop M. Kantarjian, Michael J. Keating, Ronald S. Walters,

Cancer

1986

74

Phenotypic and molecular heterogeneity in Philadelphia chromosome- positive acute leukemia

C Hirsch-Ginsberg, Craig C. Childs, KS Chang,

Blood

1988

72

Page 1